Millions of people consume low-calorie sweeteners daily while also taking medications or drinking caffeine-containing beverages — yet the combined effects of these compounds on gut bacteria have been almost entirely unstudied. This research closes a meaningful gap by mapping interactions at a scale and resolution rarely attempted in microbiome science, and the results raise questions that extend well beyond sweetener safety alone.
Using 25 phylogenetically diverse gut bacterial strains, investigators screened 39 commercially available sweeteners, both alone and in combination with four commonly co-consumed compounds: advantame, caffeine, vanillin, and the antidepressant duloxetine. Three-quarters of the sweeteners individually altered growth in at least one bacterial strain. More striking were the combinatorial effects: over 100 interaction pairs emerged, with one combination standing out sharply. Isosteviol — a metabolite and commercial component of stevia-derived sweeteners — combined synergistically with duloxetine to suppress Roseburia intestinalis, a butyrate-producing bacterium tied to glucose regulation, and Parabacteroides merdae, a commensal associated with microbiome health. Proteomic, metabolomic, and genetic analyses pointed to disrupted small-molecule transport as the mechanistic driver. When a synthetic gut bacterial community was exposed to this combination, downstream metabolic output became toxic to HeLa cells and altered IL-6 and IL-8 secretion in intestinal epithelial Caco-2 cells.
This study is methodologically ambitious — combining multi-omics with community-level functional readouts — but critical limitations apply. All experiments were conducted in vitro; no animal or human data confirm these effects occur at physiologically relevant concentrations in vivo. The duloxetine-isosteviol combination is one of billions of possible co-exposure scenarios, and selective reporting of striking pairs is an inherent limitation of high-throughput screens. Still, the finding that a widely consumed sweetener component can synergize with a top-prescribed antidepressant to suppress health-associated gut bacteria is genuinely novel. It shifts the conversation from 'are sweeteners safe in isolation' to 'what happens in the complex chemical environment of an actual human gut.' That reframe alone makes this an important incremental-to-moderate advance warranting human dietary pharmacokinetic follow-up.